Clinical Trial Update: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy and safety of oral E5501 plus standard of care for adults with chronic immune thrombocytopenia; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Thrombocytopenia

Drugs mentioned

• E5501

Snippet

Sponsor: Eisai Inc. | Conditions: Chronic Thrombocytopenia, Immune Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2018-01-05